DuBois, Steven G.

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 2,824

Larotrectinib in Patients with TRK Fusion-Positive Solid Tumours: A Pooled Analysis of Three Phase 1/2 Clinical Trials

Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 1,028

Genome-Informed Targeted Therapy for Osteosarcoma

Sayles, L. C., Breese, M. R., Koehne, A. L., Leung, S. G., Lee, A. G., Liu, H.-Y., Spillinger, A., Shah, A. T., Tanasa, B., Straessler, K., et al. (2019) · Cancer Discovery

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 452

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Geoerger, B., Kang, H. J., Yalon-Oren, M., Marshall, L. V., Vezina, C., Pappo, A., Laetsch, T. W., Petrilli, A. S., Ebinger, M., Toporski, J., et al. (2020) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 357

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study

Harris, M. H., DuBois, S. G., Glade Bender, J. L., Kim, A., Crompton, B. D., Parker, E., Dumont, I. P., Hong, A. L., Guo, D., Church, A., et al. (2016) · JAMA Oncology

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 206

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group

Shulman, D. S., Klega, K., Imamovic-Tuco, A., Clapp, A., Nag, A., Thorner, A. R., Van Allen, E., Ha, G., Lessnick, S. L., Gorlick, R., et al. (2018) · British Journal of Cancer

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 149

Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas

Pal, S., Kozono, D., Yang, X., Fendler, W., Fitts, W., Ni, J., Alberta, J. A., Zhao, J., Liu, K. X., Bian, J., et al. (2018) · Cancer Research

Glioma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 101

Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies

Abbou, S. D., Shulman, D. S., DuBois, S. G., & Crompton, B. D. (2019) · Pediatric Blood & Cancer

Cancer Genomics and DiagnosticsPrenatal Screening and Diagnostics

Cited by 72

Dose Escalation Study of No-Carrier-Added 131I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial

Matthay, K. K., Weiss, B., Villablanca, J. G., Maris, J. M., Yanik, G. A., DuBois, S. G., Stubbs, J., Groshen, S., Tsao-Wei, D., Hawkins, R., et al. (2012) · Journal of Nuclear Medicine

Neuroblastoma Research and TreatmentsRadiopharmaceutical Chemistry and Applications

Cited by 67

Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children’s Oncology Group ANBL0532 Study

Liu, K. X., Naranjo, A., Zhang, F. F., DuBois, S. G., Braunstein, S. E., Voss, S. D., Khanna, G., London, W. B., Doski, J. J., Geiger, J. D., et al. (2020) · Journal of Clinical Oncology

Neuroblastoma Research and TreatmentsGlioma Diagnosis and Treatment

Cited by 60

Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

Abbou, S., Klega, K., Tsuji, J., Tanhaemami, M., Hall, D., Barkauskas, D. A., Krailo, M. D., Cibulskis, C., Nag, A., Thorner, A. R., et al. (2023) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 44

Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas

Pearson, A. D., Gaspar, N., Janeway, K., Campbell-Hewson, Q., Lawlor, E. R., Copland, C., Karres, D., Norga, K., Benzaghou, F., Weiner, S., et al. (2022) · European Journal of Cancer

Sarcoma Diagnosis and TreatmentPharmaceutical studies and practices

Cited by 22

Prospective evaluation of pre-treatment ctDNA burden in localized osteosarcoma to identify patients with inferior outcomes: A report from the LEOPARD study.

Shulman, D. S., Klega, K. S., Chen, N., Gohn, E., Henry, D., Choy, E., Cash, T., Schultz, K. A. P., Mascarenhas, L., Bagatell, R., et al. (2024) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 8

Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.

Church, A. J., Corson, L., Kao, P.-C., Imamovic-Tuco, A., Kang, W., Pinto, N. R., Maese, L., Laetsch, T. W., Kim, A., Colace, S., et al. (2021) · Journal of Clinical Oncology

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 2

Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study

Roberts, H. J., Comeau, H., Klega, K., DuBois, S. G., Lazo de la Vega, L., Ceca, E., Mullen, E. A., Smith, G. A., Tukachinsky, H., Huang, R. S. P., et al. (2026) · JCO Precision Oncology

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 0